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Introduction: In vitro apoptosis of peripheral monocytes in rheumatoid arthritis (RA) is disturbed and influenced by
cytokine production and transmembrane TNF (tmTNF) reverse signaling. The goal of the study was the analysis of
the predictive value of the rate of in vitro apoptosis for the therapeutic response to anti-TNF treatment.
Methods: Spontaneous and tmTNF reverse signaling-induced apoptosis were determined in vitro in monocytes
from 20 RA patients prior to initiation of therapeutic TNF inhibition with etanercept, and the subsequent clinical
response was monitored.
Results: Spontaneous in vitro apoptosis was significantly reduced in RA patients compared to controls. Deficiency
in spontaneous apoptosis was associated with an insufficient therapeutic response according to the European
League Against Rheumatism (EULAR) response criteria and less reduction of the disease activity determined by
disease activity score (DAS) 28. High susceptibility to reverse signaling-induced apoptosis was also associated with
less efficient reduction in the DAS28. Of note, a strong negative correlation between the two apoptotic parameters
was discernible, possibly indicative of two pathogenetically relevant processes counter-regulating each other.
tmTNF reverse signaling induced in vitro production of soluble IL1-RI and IL-1RII only in monocytes not deficient in
spontaneous apoptosis, and the levels of soluble IL1-RII were found to be predictive of a good clinical response to
Etanercept.
Conclusion: Although tmTNF reverse signaling is able to induce apoptosis of RA monocytes in vitro, this process
appears to occur in vitro preferentially in patients with suboptimal therapeutic response. Resistance to spontaneous
in vitro apoptosis, in contrast, is a predictor of insufficient response to treatment.Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune
disease primarily affecting diarthrodial joints of hand
and feet, but clinical patterns vary widely. Inflammatory
synovitis and subsequent joint destruction in RA is to a
large extent driven by the monocytic cytokines TNF, IL-
6 and IL-1β. Therapeutic cytokine inhibition, and in par-
ticular inhibition of TNF, is highly effective in a high* Correspondence: ulf.wagner@medizin.uni-leipzig.de
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reproduction in any medium, provided the orpercentage of patients. The precise mode of action of
therapeutic TNF blockade is not clear, and several mech-
anisms have been suggested. Neutralization of soluble as
well as membrane-anchored TNF is believed to be the
primary mechanism behind the clinical efficacy in pre-
venting joint destruction, but as an alternative mode of
action of TNF-blocking agents, outside-to-inside signals
through transmembrane TNF-alpha has also been sug-
gested [1,2]. The latter is likely to contribute to certain
anti-TNF effects exerted on immune cells such as migra-
tory inhibition [3] and increased apoptosis [4].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ences in monocyte apoptosis between RA patients and
healthy donors. Monocytes from healthy controls undergo
spontaneous apoptosis (SIA) in vitro at considerable rates
during incubation over 16 hours. In monocytes from RA
patients, SIA is significantly reduced [5]. Deficient spon-
taneous in vitro apoptosis has also been reported by other
groups for peripheral monocytes from patients with sys-
temic juvenile idiopathic arthritis [6] and for monocytic
cells from the rheumatoid synovium [7,8].
In addition to deficient SIA, monocytes from RA pa-
tients are also abnormally susceptible to in vitro apop-
tosis induced by incubation with TNF-blocking agents.
The in vitro mode of action of those agents is ligation-
triggered reverse signaling (RS) of the transmembrane
TNF molecule (tmTNF) [9], which induces the in vitro
apoptosis (tmTNF reverse signaling-induced apoptosis,
tmTNF RSA) [5]. One mechanism leading to tmTNF
RSA is the inhibition of the excessive IL-1β secretion of
RA monocytes via tmTNF RS [5].
Several members of the IL-1 family of cytokines and
receptors are involved in the pathogenesis and the regu-
lation of disease activity in RA. IL-1β is overexpressed in
arthritic joints, and therapeutic inhibition of IL-1β with
anakinra is an established treatment option. IL-1β (as well
as IL-1α) binds to the transmembrane ligand-binding
chain of the IL-1 receptor (termed IL-1R type I) as well as
to the IL-1 receptor type II (IL-1RII), which lacks a cyto-
plasmic domain and functions as a decoy receptor for
IL-1β [10,11]. Both receptors can be released from the
cell surface in a soluble form as IL-1sRI and IL-1sRII, but
increased neutralization capacity had been shown for
IL-1sRI [12].
In the present study, we have investigated both
spontaneous in vitro apoptosis and consequences of
tmTNF RS in a cohort of RA patients, treated subse-
quently with the TNF inhibitor etanercept. The re-
sults show that the RA-specific, abnormal in vitro
apoptosis of RA patients is a predictor of their subse-
quent clinical response.
Methods
Patients and study design
The design of the clinical study had been approved by
the ethics committee of the University of Leipzig, and
informed consent was obtained from each patient before
study enrollment. A total of 33 patients with RA accord-
ing to the revised criteria of the American College of
Rheumatology [13] was recruited. None of the patients
had previously been treated with TNF inhibitors. Ten
healthy donors served as controls. For the initial pre-study
cohort, 13 patients with a mean age of 64 years and mean
disease duration of 16 years were recruited: 11 of these pa-
tients (78%) were seropositive for rheumatoid factor IgM(RF IgM), and 9 patients (75%) had anti-cyclic citrullinated
peptid (anti-CCP) antibodies.
In the longitudinal clinical study, 20 patients were ini-
tiated on treatment with etanercept due to clinical re-
quirements and clinical and laboratory parameters of
disease activity were monitored at baseline and through-
out the study. In this cohort, the mean age was 53 years,
and the mean disease duration was 4 years: 65% of the
patients were RF IgM-seropositive, and 80% had anti-CCP
antibodies. At baseline, 80% (16 patients) were treated
with conventional disease-modifying anti-rheumatic drugs
(DMARDs), given either as monotherapy or in combin-
ation, and 20% received low-dose glucocorticoids only. All
patients were treated with non-steroidal anti-inflammatory
drugs (NSAIDs) for symptomatic relief. All concomitant
medication remained unchanged upon initiation of etaner-
cept treatment and throughout the study.Monocyte isolation, cell culture and cell stimulation
Monocytes from peripheral blood were separated as pre-
viously described [9]: 2 × 105 monocytes per 200 μl were
incubated in Roswell Park Memorial Institute medium
(RPMI) 1640 supplemented with 5% human AB serum
(heat inactivated). Stimulation of cells was carried out ei-
ther with 100 mg/ml rituximab (Roche, Basel, Switzerland)
as an IgG control or with the soluble TNFR2:Ig construct
etanercept (Pfizer, New York, NY, USA) for 16 hours.Apoptosis detection
Staining of apoptotic and necrotic cells was performed by
using 10 μl allophycocyanin-labeled Annnexin V (Southern
Biotechnology, Birmingham, AL, USA) and 50 μg/ml pro-
pidium iodide (IP), respectively. Fluorescence was mea-
sured on the FACSCalibur system, and the results were
analyzed using FlowJo software (Tree Star, Inc, Ashland,
OR, USA).Cytokine detection
Cytokine levels in cell culture supernatants were measured
with cytometric bead arrays (BD biosciences, Franklin
Lakes, NJ, USA) according to the manufacturer's protocol.Statistics
For statistical analysis, graphPad Prism software (Graph-
Pad Software, La Jolla, CA, USA) was used. Prior to all
comparisons, a normality test was performed. To assess
statistical significance, Student’s t-test (normal distri-
bution of data) or the Mann–Whitney rank sum test
(unequal distribution of data) was used. Correlation
between two parameters was analyzed with Pearson’s
product–moment correlation.
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The soluble TNFR2: Ig construct etanercept triggers
tmTNF RSA in RA monocytes
We have shown previously, that ligation of tmTNF by
anti-TNF antibodies induces apoptosis in RA monocytes
through triggering tmTNF RS [5]. In addition, this study
found a decreased rate of spontaneous in vitro apoptosis
in monocytes from RA patients compared to healthy con-
trols. For the present study, an initial pre-study investiga-
tion confirmed the lower rate of spontaneous monocyte
apoptosis in RA patients compared to healthy controls
(RA: 18.92 ± 13.56% versus healthy donors (HD): 32.44 ±
10.52%, P = 0.016, Figure 1A,B). Triggering of tmTNF
RS by ligation with the soluble TNFR2:Ig construct
etanercept yielded rates of tmTNF RSA that were
similar to those obtained with the anti-TNF antibody in
our previous study [5]. The median rate of tmTNF RSA in
RA patients was 1.6-fold higher than the spontaneous
apoptosis (tmTNF RSA: 28.56 ± 9.1% versus SIA: 18.92 ±
13.56%, n = 13, P = 0.003, Figure 1A), whereas RS did not
influence the rate of in vitro apoptosis in healthy controls
(32.64 ± 12.20 versus 32.44 ± 10.52, n = 10, not significant,
Figure 1A). As etanercept was used in the treatment of
the patients in the study, it was also chosen as the TNF-
blocking agent for the in vitro experiments in the longitu-
dinal study presented here.Figure 1 TNFR2:Ig triggered reverse signaling via transmembrane (tm
(RA) patients but not from healthy controls. (A) Monocytes from the pe
cultured with IgG or TNFR2:Ig for 16 hours. Box plot depicts the rate of spo
of tmTNF reverse signaling-induced apoptosis (tmTNF RSA) in the presence
patients (RA) (n = 13). Significant differences are as indicated. (B) Represent
from a healthy control (left panels) and from one RA patient (right panels)
spontaneous apoptosis in vitro (SIA) (IgG), lower panels tmTNF reverse signDeficient SIA is a predictor of insufficient therapeutic
response
Clinical characteristics of the main study cohort and
parameters of disease activity at baseline and after 12
weeks of TNF blockade are summarized in Table 1.
After 12 weeks, 50% of the patients achieved a good clin-
ical response according to the European League Against
Rheumatism (EULAR) response criteria for RA [14], whereas
50% achieved only a moderate response or no response.
At baseline, no influence on the DAS28 or of individ-
ual parameters of disease activity (swollen or tender joint
count, visual analog scale (VAS) or acute-phase reac-
tants) on the rate of spontaneous monocyte apoptosis
was detectable (Table 1). The baseline percentage of
spontaneously apoptotic monocytes did closely correlate,
however, with the reduction in DAS28 observed during
the initial 12 weeks of therapy (Figure 2A). Similar re-
sults were obtained for the change in C-reactive protein
(CRP) and erythrocyte sedimentation rate (ESR) values
over 12 weeks (Figure 2B,C). When patients were sepa-
rated into a group with high SIA comparable to healthy
donors, and a group with diminished SIA, a clear separ-
ation in the clinical response became apparent. Patients
with diminished monocyte SIA did not respond to treat-
ment with a reduction in DAS28, and had significantly less
reduction in DAS28 in comparison to the group with high)TNF induces apoptosis in monocytes from rheumatoid arthritis
ripheral blood of healthy donors (HD) and from RA patients (RA) were
ntaneous apoptosis in vitro (SIA) cultures with IgG (dark gray bars) and
of TNFR2:Ig (light gray bars) in healthy controls (HD) (n = 10) and RA
ative dot plots of annexin V- and propidium iodide-stained monocytes
after incubation with IgG or TNFR2:Ig for 16 hours. Upper panels show
aling induced apoptosis (tmTNF RSA) (TNFR2:Ig).




Responder (week 12) Nonresponder (week 12) All patients Responder Nonresponder
Number 20 10 10 20 10 10
TJC of 28 joints 8.25 (±7.2) 9.20 (±8.7) 7.30 (±5.8) 3.16 (±3.3) 2.20 (±3,2) 4.22 (±3.3)
SJC of 28 joints 5.45 (±3.7) 5.90 (±3.1) 5.00 (±4.3) 1.79 (±2.7) 0.70 (±1.9) 3.00 (±3.1)
VAS general disease activity 47.8 (±20.4) 52.6 (±19.3) 42.9 (±21.4) 27.6 (±18.6) 21.6 (±16.9) 34.2 (±19.1)
ESR, mm/h 23.7 (±13.6) 19.1 (±10.5) 28.3 (±15.3) 17.8 (±14.2) 11.1 (±7.3) 25.1 (±16.7)
C reactive protein, mg/dl 7.22 (±6.5) 6.65 (±4.9) 7.79 (±8.0) 5.40 (±8.9) 2.71 (±3.1) 8.3 (±12.3)
DAS28 4.76 (±1.2) 4.82 (±1.2) 4.7 (±1.2) 3.33 (±1.4) 2.50 (±1.1) 4.17 (±1.2)
Age, years 53.65 (±9.4) 53.5 (±10.7) 53.8 (±8.5) - - -
Sex, female, % 70 60 80 - - -
Disease duration, years 4.35 4.3 4.4 - - -
Rheumatoid factor, +/−, % 65/35 70/30 60/40 - - -
Anti CCP, +/−, % 80/20 80/20 80/20 - -
TJC, tender joint count; SJC, swollen joint count; VAS, visual analog scale; ESR, erythrocyte sedimentation rate; DAS28, disease activity score in 28 joints; CCP, cyclic
citrullinated peptide.
Figure 2 Spontaneous in vitro apoptosis of monocytes correlates with change in disease activity after 12 weeks. (A-C) Spontaneous
apoptosis of monocytes from rheumatoid arthritis (RA) patients was measured at baseline and the change in disease activity score (DAS)28,
C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) levels from baseline and to week 12 after starting treatment with etanercept for
these patients was calculated. Dot plots depict the rate of spontaneous in vitro apoptosis (SIA) in relation to the change (Δ) in DAS28 (A), CRP
(B) and ESR (C) (n = 20). Regression coefficient and level of significance for the linear regression are as indicated. (D) Processing of DAS28 during
the study was analyzed in the patient cohorts with high and low spontaneous monocyte apoptosis respectively. Change in DAS28 was calculated
for the treatment time points 4, 8 12, 16 and 24 weeks. Depicted are median and standard error of the mean of numeric improvement in DAS28
(ΔDAS28) in the patient group with high (solid squares) and low (solid circles) rates of spontaneous in vitro SIA at baseline (BL) at indicated time
points (n = 20). For significant differences between ΔDAS28 in both groups at different time points, significance levels are indicted: *P <0.05,
**P <0.01. (E) Dot plot depicts the rate of spontaneous in vitro SIA in patients achieving a good therapeutic response after 12 weeks of etanercept
(responder, Resp) (n = 20) and in patients with only moderate or no response (nonresponders, Nonresp). Significant differences are as indicated.
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time points (Figure 2D). Consequently, patients with a
good clinical response according to the EULAR criteria
had a higher rate of monocyte SIA at baseline than pa-
tients with moderate response or no response (Figure 2E).
tmTNF reverse signaling induces secretion of IL-1sRI and
IL-1sRII in vitro only in monocytes susceptible to high SIA
We have shown previously, that RS after ligation of
tmTNF by anti-TNF inhibits constitutive NF-kB activation
and IL-1β secretion, which subsequently increases in vitroFigure 3 Transmembrane (tm)TNF reverse signaling (RS)-induced secr
and influences clinical response. (A, B) tmTNF RS-induced IL-1RI and IL-1
rheumatoid arthritis (RA) patients after baseline incubation IgG and TNFR2:I
(B) concentrations in control cultures (IgG) (solid circles) and in cultures with
from the subgroup of RA patients (n = 10) characterized by high rates of spon
are indicated. (C) Levels of tmTNF RS-induced IL-1RI production (ΔIL-1sRI) by
apoptosis in these RA patients. Dot plots depicts rate of SIA in relation
ΔIL-1sRI is the difference of tmTNF RS-induced IL-1sRI production and spo
for linear regression are indicated. (D) Levels of baseline tmTNF RS-induced IL
in disease activity score (DAS)28 12 weeks after starting treatment. Dot plots d
weeks of TNF blockade in relation to the concentration of tmTNF RS-induce
RS-induced IL-1sRII production and spontaneous IL-1sRII production. Regre
as indicated.apoptosis of monocytes, and which might also contribute
to the therapeutic efficacy of TNF inhibitors [5]. Therefore,
to investigate consequences of tmTNF RS in the present
study, a wider approach was taken by determining concen-
trations of IL-1α, IL-1β, IL-1sRI and IL-1sRII in the super-
natant of cultures with TNFR2: Ig using a cytometric bead
array. No significant effect of tmTNF RS on the secretion
of IL-1α or IL-1β was detectable (data not shown). Secre-
tion of both IL-1sRI and IL-1sRII, however, was found to
increase significantly following tmTNF RS, but only in
monocytes with high SIA (Figure 3A and B). No increaseetion of soluble IL1-RI and IL1-RII depends on apoptotic rates
RII expression was measured in in vitro monocyte cultures from
g for 16 hours. Individually paired data of IL1sRI (A) and IL1sRII
TNFR2:Ig (solid triangles) determined in vitro at baseline in monocytes
taneous in vitro apoptosis (SIA) are as indicated. Significant differences
RA monocytes at baseline correlates with spontaneous monocyte
to the baseline concentration of tmTNF RS-induced IL1sRI (n = 18).
ntaneous IL-1sRI production. Regression coefficient and significane level
-1RII production by RA monocytes correlated negatively with change (Δ)
epicts numeric improvement in (ΔDAS28) in RA patients (n = 18) after 12
d IL1-sRII (ΔIL-1sRII) at baseline. ΔIL-1sRII is the difference in tmTNF
ssion coefficient and level of significance for the linear regression are
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diminished SIA (data not shown). Furthermore, SIA was
found to be linked to tmTNF RS-induced IL-1sRI secre-
tion of the monocytes, as a positive correlation between
IL-1sRI concentrations and the rate of spontaneous apop-
tosis became apparent (Figure 3C). Spontaneous secretion
of IL-1α and IL-1β in contrast, did not differ between pa-
tients with high or low spontaneous apoptosis.
For IL-1sRII, a significant negative correlation of the
concentrations induced by tmTNF RS with the reduction
in the DAS28 after 12 weeks was detected (Figure 3D),
whereas a similar trend for IL-1sRI did not reach statis-
tical significance (R = −0.333; P = 0.177).
High susceptibility of monocytes to tmTNF RSA at
baseline is associated with insufficient therapeutic
response
In addition to tmTNF RS-induced production of IL-1α,
IL-1β and the two receptors, we also measured tmTNF
RSA. In accordance with the results from previous stud-
ies [5], significant rates of RSA were only observed in
monocytes with upregulated tmTNF expression (data notFigure 4 Monocytes with low spontaneous in vitro apoptosis are susc
apoptosis (tmTNF RSA). (A) Dot plot shows the rate of spontaneous in vi
(RA) patients (n = 20). tmTNF RSA is shown as ratio of TNFR2:Ig apoptosis a
regression are as indicated. (B) Box plot depicts the rate of tmTNF RSA (lig
groups with high and low tmTNF RSA separately (n = 20). Significant differe
propidium iodide-stained monocytes from one patient with high tmTNF RS
show SIA (IgG), lower panels TNF RSA (TNFR2:Ig).shown). Parallel analysis of SIA and of tmTNF RSA at
baseline showed a highly significant inverse correlation
between the two parameters (P = 0.0075, R = −0.5791,
Figure 4A,B). When the patient cohort was separated
into one group with low susceptiblity to tmTNF RSA
and one with high rates of RSA, the two groups were
found to differ also in their spontaneous apoptotic
rates (Figure 4C).
The clinical analysis showed that only RA patients in
the low tmTNF RSA group responded with a significant
decrease of CRP (Figure 5A) and ESR (Figure 5B) dur-
ing the initial 12 weeks of therapeutic TNF blockade,
whereas the high tmTNF RSA group did not. Accord-
ingly, the reduction in DAS28 (ΔDAS28) was signifi-
cantly higher at all time points in the group with low
tmTNF RSA at baseline (Figure 5C), and such resistance
to tmTNF RSA at baseline was associated with a good
clinical response to TNF blockade after 12 weeks ac-
cording to the EULAR criteria (Figure 5D). Suscepti-
bility to tmTNF RSA at baseline, in contrast, was a
predictor for only moderate response or no response
at all (Figure 5D).eptible for transmembrane TNF reverse signaling-induced
tro apoptosis (SIA) in relation to tmTNF RSA) in rheumatoid arthritis
nd SIA. Regression coefficient and level of significance for the linear
ht gray bars, TNFR2:Ig) in comparison to SIA (dark gray bars, IgG) in the
nces are as indicated. (C) Representative dot plots of annexin V- and
A (left panels) and one with low TNF RSA (right panels). Upper panels
Figure 5 Transmembrane (tm)TNF reverse signaling induced apoptosis of monocytes correlates with change in disease activity after
12 weeks. (A, B) Box plots depict C-reactive protein (CRP) (A) and erythrocyte sedimentation rate (ESR) (B) at baseline (BL) (dark gray bars) and
after 12 weeks of etanercept (light gray bars) in the groups with high tmTNF reverse signaling induced apoptosis (tmTNF RSA) and low tm tmTNF
RSA separately (n = 20). Significant differences are as indicated. (C) Depicted are median and standard error of the mean of the numeric improvement
(Δ) in disease activity score (DAS)28 in the patient group with high (solid squares, n = 11) and low (solid circles, n = 9) rates of tmTNF RSA at
the indicated time points. For significant differences between ΔDAS28 in both groups at the different time points, the levels of significance are
indicated: *P <0.05, **P <0.01). (D) Dot plot depicts the rate of tmTNF RSA in patients achieving a good therapeutic response after 12 weeks of
etanercept (responder, Resp) and in patients with only a moderate or no response (nonresponders, Nonresp). Significant differences are as indicated.
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The goal of our study was the investigation of spontan-
eous and tmTNF RS-induced monocyte apoptosis in RA
patients before the initiation of therapeutic TNF block-
ade, followed by a longitudinal analysis of the clinical
response. In this longitudinal analysis, a significant in-
fluence of decreased SIA on the clinical response to
anti-TNF was revealed. The SIA of monocytes from
patients with a good clinical response was higher than
from nonresponders and comparable to the healthy
controls in the pre-study investigation. Deficient SIA,
on the other hand, was predictive of an insufficient
therapeutic response, suggesting that monocyte apop-
tosis might also be involved in therapeutic response
to TNF blockade. As the patients were not initiated
on any conventional DMARD therapy in the study,
we can only speculate upon the contribution of SIA
towards methotrexate (MTX) response.Resistance to in vitro apoptosis has been described to
occur as a consequence of activation of human monocytes
[15]. As several signs of activation of monocytes in RA
have been described [16,17], this mechanism could indeed
contribute to the observed decrease of SIA in RA patients.
Accordingly, we have reported previously that the deficient
SIA of RA monocytes is partly due to increased spontan-
eous IL-1β secretion and constitutively activated NF-kB
signaling [5]. Therefore, activation of circulating mono-
cytes is a likely cause for the deficient SIA in half of the
study cohort, and might also contribute to the unfavorable
therapeutic outcome in those patients. In addition, overex-
pression of anti-apoptotic molecules such as FLIP [7] or
self-sustained NF-kB activation [18] have been described
in RA, which could further reinforce resistance to apop-
tosis. An alternative hypothesis would be the existence of
an RA-specific apoptotic defect, which aggravates the dis-
ease due to survival of pro-inflammatory monocytes.
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One previously unknown finding of our study was the
secretion of both type I IL-1sR (IL-1sRI) and type II IL-
1sR (IL-1sRII) into the supernatant of monocytes follow-
ing TNFR2:Ig-triggered tmTNF RS. This is in contrast
to a previous publication reporting that treatment with
TNFR2:Ig has no influence on the expression of cell sur-
face IL-1RII in vivo [19], but circulating or local levels of
IL-1sRII had not been determined in that study.
IL-1sRII is known to bind IL-1β with higher avidity
than IL-1sRI, while not interfering with the binding of
IL-1 receptor antagonist (IL-1RA) [20]. IL-1sRII has also
been reported to be expressed in higher concentrations
in the synovial fluid of RA patients [20]. Importantly,
the simultaneous addition of IL-1sRII and IL-1RA to
cultures of synovial cells leads to a synergistic inhibitory
effect on the secretion of interstitial collagenase and
prostaglandine E2 (PGE2) [21], indicating a potentially
relevant role for IL-1sRII in the rheumatoid synovium
in vivo. In an analogous conclusion, shedded IL-1sRII
has also been suggested to act locally by dampening co-
lonic inflammation in Crohn’s disease [22].
The essential role of the IL-1β-IL1-R system for the
RA-specific resistance of monocytes against SIA was
confirmed in the present study, when a positive correl-
ation between the tmTNF RS induced IL-1sRI secretion
of monocytes and their spontaneous apoptosis became
apparent. This correlation indicates that the ability of
cells to respond to tmTNF RS with production of IL1sRI
is linked to their susceptibility to spontaneous apoptosis.Figure 6 Schematic representation of the magnitude of spontaneous
signaling-induced apoptosis (tmTNF RSA) in healthy donors (HD) and
tmTNF RSA is associated with both disease severity and the clinical responOne possible explanation is, that the cells prone to spon-
taneous apoptosis are also the ones shedding IL-1sRI
upon triggering of tmTNF RS. Indeed, high concentra-
tions of IL-1sRI and IL-1sRII were detectable only in
monocytes with high spontaneous apoptosis (that is, in
monocytes from patients with a good therapeutic re-
sponse), which indicates that IL-1R secretion might also
be beneficial in vivo. The close correlation between IL-
1sRII and the decrease in the DAS28 indicates that IL1R
secretion might also be therapeutically relevant.
The observed negative correlation between SIA and
tmTNF RSA indicates that the latter only occurs in
patients with a pathologic resistance to spontaneous
apoptosis. In healthy controls, tmTNF RSA cannot be
triggered [5], and patients with low tmTNF RSA were
also the ones with a good clinical response to anti-TNF
therapy. Nevertheless, this lack of tmTNF RSA in anti-
TNF responders in vitro does not exclude a contribution
of tmTNF RSA to the clinical efficacy of TNF blockade
in vivo. In the synovial membrane, TNF blockade has
indeed been linked to monocyte/macrophage apoptosis
[23], although other studies detected no immediate mono-
cyte apoptosis in the peripheral blood or the rheumatoid
synovium following anti-TNF antibody infusion [24,25].
The latter would argue against a therapeutic effect of
tmTNF RSA, which might instead be an indicator for the
pathological state of activation of monocytes in RA. Simi-
larly, RA monocytes are also characterized by expression
of tmTNF, which correlates with the rate of tmTNF RSA,
whereas monocytes from healthy donors do not expressin vitro apoptosis (SIA) and transmembrane TNF reverse
patients with rheumatoid arthritis (RA). A shift from SIA towards
se under anti-TNF treatment.
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tmTNF RSA in anti-TNF responders could be the result
of a lack of tmTNF expression in those patients, which in
turn might be an indicator of less severe disease.
Finally, tmTNF RS could also be part of a pro-
inflammatory pathway, which is aggravating the course of
RA, possibly during direct cell-cell contact [9]. Conse-
quently, the non-responders to therapeutic TNF blockade
could be the patients in whom those pro-inflammatory ef-
fects of tmTNF ligation by therapeutic anti-TNF com-
pounds outweigh the beneficial effects of TNF blockade.
Accordingly, RS in non-responders can induce apoptosis
in vitro, but might still be deleterious to the patient due to
those pro-inflammatory effects. Consequently, high rates
of tmTNF RSA predict poor therapeutic response.
Conclusion
In conclusion, we have shown that both deficient SIA
and high tmTNF RSA are associated with an unfavorable
outcome of TNF blockade. Ultimately, it is unclear
whether resistance to SIA or increased tmTNF RSA is
the primary predictor of an insufficient response, be-
cause both parameters are closely related. The findings
indicate that those deviations from the pattern seen in
healthy controls (which is characterized by high SIA and
resistance to tmTNF RSA) are not only hallmarks of RA
per se, but are also predictors of treatment failures
(Figure 6). Consequently, apoptotic pathways are likely to
be involved in both the pathogenesis of the disease and
the therapeutic response to TNF blockade in RA.
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necrosis factor receptor 2:immunoglobulin fusion protein; VAS: Visual analog
scale.
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